See more : Kjell Group AB (publ) (KJELL.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Adagene Inc. (ADAG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adagene Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nuchev Limited (NUC.AX) Income Statement Analysis – Financial Results
- Profile Systems & Software SA (PROF.AT) Income Statement Analysis – Financial Results
- Align Technology, Inc. (0HCK.L) Income Statement Analysis – Financial Results
- Discover Financial Services (0IBC.L) Income Statement Analysis – Financial Results
- Atam Valves Limited (ATAM.BO) Income Statement Analysis – Financial Results
Adagene Inc. (ADAG)
About Adagene Inc.
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 18.11M | 9.29M | 10.18M | 480.00K | 480.00K | 1.51M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 18.11M | 9.29M | 10.18M | 480.00K | 480.00K | 1.51M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 36.64M | 81.34M | 68.10M | 16.21M | 16.21M | 16.08M |
| General & Administrative | 8.67M | 11.87M | 14.44M | 3.44M | 3.44M | 2.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.67M | 11.87M | 14.44M | 3.44M | 3.44M | 2.77M |
| Other Expenses | -3.48M | 2.17M | 1.78M | 723.48K | 723.48K | 901.71K |
| Operating Expenses | 41.83M | 93.21M | 82.54M | 19.65M | 19.65M | 18.85M |
| Cost & Expenses | 41.83M | 93.21M | 82.54M | 19.65M | 19.65M | 18.85M |
| Interest Income | 4.28M | 377.50K | 76.17K | 922.68K | 922.68K | 710.71K |
| Interest Expense | 1.11M | 693.32K | 363.76K | 138.10K | 138.10K | 91.09K |
| Depreciation & Amortization | 1.21M | 1.43M | 1.13M | 858.41K | 816.69K | 909.00K |
| EBITDA | -14.95M | -77.39M | -69.99M | -41.34M | -15.48M | -14.27M |
| EBITDA Ratio | -82.55% | -875.68% | -692.95% | -3,650.73% | -3,480.59% | -980.24% |
| Operating Income | -23.72M | -83.92M | -72.36M | -19.17M | -19.17M | -17.33M |
| Operating Income Ratio | -130.97% | -903.08% | -711.18% | -3,993.68% | -3,993.68% | -1,147.09% |
| Total Other Income/Expenses | 6.46M | 4.41M | 887.77K | 754.38K | 2.74M | 2.07M |
| Income Before Tax | -17.25M | -79.51M | -71.48M | -16.43M | -16.43M | -15.27M |
| Income Before Tax Ratio | -95.27% | -855.65% | -702.45% | -3,423.40% | -3,423.40% | -1,010.22% |
| Income Tax Expense | 1.69M | 459.06K | 1.70M | 3.16K | 861.57K | -547.00K |
| Net Income | -18.95M | -79.97M | -73.18M | -16.44M | -17.29M | -14.72M |
| Net Income Ratio | -104.61% | -860.59% | -719.18% | -3,424.06% | -3,602.89% | -974.03% |
| EPS | -0.44 | -1.85 | -1.83 | -0.47 | -0.39 | -0.43 |
| EPS Diluted | -0.43 | -1.85 | -1.83 | -0.47 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 43.31M | 43.31M | 40.03M | 35.08M | 44.17M | 34.41M |
| Weighted Avg Shares Out (Dil) | 43.79M | 43.31M | 40.03M | 35.08M | 44.17M | 34.41M |
Adagene to Present at Upcoming Investor Conferences
Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting
Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021
Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates
Adagene Announces Clinical Advancement for ADG116
Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
U.S. IPO Weekly Recap: IPO Frenzy Brings The Year's Largest Deal And Biggest Pop In A 17 IPO Week
Week In Review: Suzhou's Adagen Raises $140 Million In U.S. IPO To Develop Oncology Drugs
Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
Adagene Readies Plan For $132 Million U.S. IPO
Source: https://incomestatements.info
Category: Stock Reports